Vivos therapeutics announces strategic collaboration in the middle east-north africa region to support international expansion

Vivos executes distribution agreement with established dubai-based sleep testing company subject to regulatory approvals, vivos could see revenue from this collaboration in 2024 littleton, colo., oct. 05, 2023 (globe newswire) --  vivos therapeutics, inc. (the “company” or “vivos”) (nasdaq:vvos), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders, today announced it has entered into an exclusive distribution agreement with noum dmcc (“noum”), a dubai-based company focused on diagnostic testing and treatment product distribution for healthcare providers and hospital networks treating obstructive sleep apnea patients throughout the middle east-north africa (mena) region.
VVOS Ratings Summary
VVOS Quant Ranking